SG11202106082TA - Bicyclic peptide ligands specific for mt1-mmp - Google Patents

Bicyclic peptide ligands specific for mt1-mmp

Info

Publication number
SG11202106082TA
SG11202106082TA SG11202106082TA SG11202106082TA SG11202106082TA SG 11202106082T A SG11202106082T A SG 11202106082TA SG 11202106082T A SG11202106082T A SG 11202106082TA SG 11202106082T A SG11202106082T A SG 11202106082TA SG 11202106082T A SG11202106082T A SG 11202106082TA
Authority
SG
Singapore
Prior art keywords
mmp
peptide ligands
ligands specific
bicyclic peptide
bicyclic
Prior art date
Application number
SG11202106082TA
Other languages
English (en)
Inventor
Catherine Stace
Daniel Teufel
Edward Walker
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of SG11202106082TA publication Critical patent/SG11202106082TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202106082TA 2018-12-13 2019-12-13 Bicyclic peptide ligands specific for mt1-mmp SG11202106082TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820288.7A GB201820288D0 (en) 2018-12-13 2018-12-13 Bicycle peptide ligaands specific for MT1-MMP
PCT/GB2019/053537 WO2020120981A1 (en) 2018-12-13 2019-12-13 Bicyclic peptide ligands specific for mt1-mmp

Publications (1)

Publication Number Publication Date
SG11202106082TA true SG11202106082TA (en) 2021-07-29

Family

ID=65146942

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106082TA SG11202106082TA (en) 2018-12-13 2019-12-13 Bicyclic peptide ligands specific for mt1-mmp

Country Status (14)

Country Link
US (1) US20220362390A1 (ja)
EP (1) EP3894009A1 (ja)
JP (1) JP2022512478A (ja)
KR (1) KR20210123296A (ja)
CN (1) CN113474047A (ja)
AU (1) AU2019398722A1 (ja)
BR (1) BR112021011217A2 (ja)
CA (1) CA3122659A1 (ja)
EA (1) EA202191651A1 (ja)
GB (1) GB201820288D0 (ja)
IL (1) IL283874A (ja)
MX (1) MX2021006989A (ja)
SG (1) SG11202106082TA (ja)
WO (1) WO2020120981A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110603261A (zh) 2016-12-23 2019-12-20 拜斯科阿迪有限公司 具有新型键结构的肽衍生物
WO2023088236A1 (zh) * 2021-11-16 2023-05-25 海思科医药集团股份有限公司 Mt1-mmp的双环肽配体及其缀合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2474613B2 (en) 2008-02-05 2022-02-16 BicycleRD Limited Methods and compositions
CA2965754C (en) * 2014-10-29 2024-01-02 Bicycle Therapeutics Limited Bicyclic peptide ligands specific for mt1-mmp
US10624968B2 (en) * 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
GB201706477D0 (en) * 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides

Also Published As

Publication number Publication date
EA202191651A1 (ru) 2021-09-13
JP2022512478A (ja) 2022-02-04
US20220362390A1 (en) 2022-11-17
CA3122659A1 (en) 2020-06-18
WO2020120981A1 (en) 2020-06-18
GB201820288D0 (en) 2019-01-30
KR20210123296A (ko) 2021-10-13
CN113474047A (zh) 2021-10-01
BR112021011217A2 (pt) 2021-08-31
EP3894009A1 (en) 2021-10-20
MX2021006989A (es) 2021-10-13
AU2019398722A1 (en) 2021-08-05
IL283874A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
ZA202100442B (en) Bicyclic peptide ligands specific for nectin-4
IL276803A (en) Peptide ligands in multimeric cycles
IL283873A (en) Bicyclic peptide ligands specific for mt1-mmp
IL287881A (en) Ox40-specific bicyclic peptide ligands
GB201820316D0 (en) Bicyclic peptide ligands specific for IL-17
IL283874A (en) Bicyclic peptide ligands specific for mt1-mmp
GB201820325D0 (en) Bicyclic peptide ligands specific for psma
GB201820295D0 (en) Bicyclic peptide ligands specific for MT1-MMP
GB201820320D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201820286D0 (en) Bicyclic peptide ligands specific for mt1-mmp
GB201818499D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201815684D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201820321D0 (en) Bicyclic peptide ligands specific for MMP9
GB201918495D0 (en) Bicyclic peptide ligands specific for il-46
GB201904632D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201820956D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201720934D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201820322D0 (en) Bicyclic peptide ligands specific for TGFbeta
GB201712693D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201820315D0 (en) Bicyclic peptide ligands specific for IL-9
GB201820313D0 (en) Bicyclic peptide ligands specific for KLK5
GB201818158D0 (en) Multimeric bicyclic peptide ligands
GB201820318D0 (en) Bicyclic peptide ligands specific for cathepsin G
GB201820969D0 (en) Bicyclic peptide ligands specific for pd-l
GB201720928D0 (en) Bicyclic peptide ligands specific for IL-6